|
|
|
|
Sumatriptan succinate,a 5-HT1D receptor agonist,constricts human cranial arteries.Two parallel-group trials for treatment of acute migraines were conducted in the United States.Adult patients were randomized and given either 6 mg of sumatriptan succinate subcutaneously(n=734)or placebo(n= 370).At 1 hour,sumatriptan was significantly more effective than placebo in reducing moderate or severe headache pain to mild or no pain(70%vs 22%),in completely relieving headaches(49%vs 9%),and in improving clinical disability(76%vs 34%).Sumatriptan also reduced nausea and photophobia significantly better than placebo.Patients with residual migraines received either a second active injection(n=187)or placebo(n=178),while those who had received placebo received a second placebo injection(n=335). Statistical evidence for benefit of second sumatriptan injection is absent.Adverse events associated with sumatriptan were tingling,dizziness, warm-hot sensations,and injection-site reactions.Sumatriptan is effective and well tolerated in patients with acute migraine. |
|